Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Laurence Chaperot
Based on 6 articles published since 2008

Between 2008 and 2019, L. Chaperot wrote the following 6 articles about Melanoma.
+ Citations + Abstracts
1 Review Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. 2017

Busser, Benoit / Lupo, Julien / Sancey, Lucie / Mouret, Stéphane / Faure, Patrice / Plumas, Joel / Chaperot, Laurence / Leccia, Marie Thérèse / Coll, Jean Luc / Hurbin, Amandine / Hainaut, Pierre / Charles, Julie. ·Biochemistry Pharmacology and Toxicology Department, Grenoble University Hospital, Grenoble, France. · Institute for Advanced Biosciences, UGA/INSERM U1209/CNRS UMR5309, Grenoble, France. · Virology Laboratory, Grenoble University Hospital, Grenoble, France. · Institut de Biologie Structurale, CEA-CNRS UMR 5075/UGA, Grenoble, France. · Dermatology Unit, Grenoble University Hospital, Grenoble, France. · UGA, Laboratory of Hypoxy Physiopathology Study, INSERM U1042, Grenoble, France. · EFS Rhone-Alpes-Auvergne, Grenoble, France. ·Biomed Res Int · Pubmed #28484715.

ABSTRACT: Melanoma is a cutaneous cancer with an increasing worldwide prevalence and high mortality due to unresectable or metastatic stages. Mutations in

2 Article The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients. 2018

Charles, Julie / Chaperot, Laurence / Revol, Bruno / Baudin, Marine / Mouret, Stephane / Hamon, Agnes / Leccia, Marie-Therese / Plumas, Joel / Aspord, Caroline. ·University Grenoble Alpes, Grenoble, France. · Immunobiology& Immunotherapy of Chronic Diseases, U1209, INSERM, La Tronche, France. · Dermatology, Pôle Pluridisciplinaire de Médecine, CHU Grenoble Alpes, Grenoble, France. · R&D Laboratory, Etablissement Français du Sang Rhone-Alpes, La Tronche, France. · Pharmacovigilance Department, CHU Grenoble Alpes, Grenoble, France. · Laboratoire Jean Kuntzmann, Universite Grenoble Alpes, Grenoble, France. ·Pigment Cell Melanoma Res · Pubmed #28741900.

ABSTRACT: The advent of immune checkpoint blockers and targeted therapies has changed the outcome of melanoma. However, many patients experience relapses, emphasizing the need for predictive and prognostic biomarkers. We developed a strategy based on plasmacytoid dendritic cells (pDCs) loaded with melanoma tumor antigens that allows eliciting highly efficient antitumor T-cell responses. We used it to investigate antitumor T-cell functionality in peripheral blood mononuclear cells and tumor-infiltrating lymphocytes from melanoma patients. The pDCs elicited tumor-specific T cells in different proportions and displaying diverse functional features, dependent upon the stage of the disease, but independent of the histological parameters at diagnosis. Strikingly, the avidity of the MelA-specific T cells triggered by the pDCs was found to predict patient relapse time and overall survival. Our findings highlighted unexplored aspects of antitumor T-cell responsiveness in melanoma, and revealed for the first time the structural avidity of tumor-specific T cells as a crucial feature for predicting clinical evolution.

3 Article HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. 2012

Aspord, Caroline / Leccia, Marie-Therese / Salameire, Dimitri / Laurin, David / Chaperot, Laurence / Charles, Julie / Plumas, Joel. ·Etablissement Français du Sang Rhone-Alpes, R&D Laboratory, La Tronche, France; University Joseph Fourier, Grenoble, France; INSERM U823, Immunobiology & Immunotherapy of Cancers, La Tronche, France. Electronic address: carolineaspord@yahoo.com. · University Joseph Fourier, Grenoble, France; INSERM U823, Immunobiology & Immunotherapy of Cancers, La Tronche, France; Department of Dermatology, Michallon Hospital, Pôle Pluridisciplinaire de Médecine, Grenoble, France. · University Joseph Fourier, Grenoble, France; INSERM U823, Immunobiology & Immunotherapy of Cancers, La Tronche, France; Anatomo-cytopathology, Michallon Hospital, Grenoble, France. · Etablissement Français du Sang Rhone-Alpes, R&D Laboratory, La Tronche, France; University Joseph Fourier, Grenoble, France; INSERM U823, Immunobiology & Immunotherapy of Cancers, La Tronche, France. · Etablissement Français du Sang Rhone-Alpes, R&D Laboratory, La Tronche, France; University Joseph Fourier, Grenoble, France; INSERM U823, Immunobiology & Immunotherapy of Cancers, La Tronche, France; University College London, Cancer Institute, London, UK. ·J Invest Dermatol · Pubmed #22696054.

ABSTRACT: Several sources of evidence suggest that tumor-specific T cells have the potential to control melanoma tumors. Current active and adoptive therapeutic approaches to elicit such T cells are either not sufficiently clinically efficient or require fastidious processes that impede their extensive clinical use. As plasmacytoid dendritic cells (pDCs) have a crucial role in triggering antitumor immunity especially in melanoma, we explored their potential as a cell-based approach for melanoma immunotherapy. An irradiated human HLA-A(*)0201(+) pDC line loaded with peptides derived from the major melanoma tumor antigens, MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, was used to trigger functional multi-specific T cells ex vivo from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes from stage I-IV HLA-A(*)0201(+) melanoma patients. pDCs loaded with melanoma-derived peptides promptly induced high levels of melanoma tumor-specific T cells from both sources. pDC-primed central/effector memory antitumor T cells were highly functional as indicated by the specific IFNγ secretion and membrane CD107 expression upon stimulation. Cells also exhibited strong cytotoxicity toward semi-allogeneic melanoma cells and patient-derived tumor cells. The simple design and potent efficacy of this promising approach provides a preclinical basis for the development of a pDC-based vaccine and an alternative means to produce tumor-specific T cells for adoptive cellular immunotherapy in melanoma patients.

4 Article [GENiusVac, a novel antitumor vaccine strategy based on allogeneic plasmacytoid dendritic cells]. 2011

Aspord, C / Charles, J / Leccia, M-T / Laurin, D / Richard, M-J / Chaperot, L / Plumas, J. ·Inserm U823, Établissement français du sang (EFS) Rhone-Alpes, R&D Laboratory, 38701 La Tronche, France. carolineaspord@yahoo.com ·Rev Med Interne · Pubmed #21429635.

ABSTRACT: The development of effective vaccines against cancer and viruses still remains a challenge. Many immunotherapeutic strategies have been developed but without sufficient therapeutic success. Plasmacytoid dendritic cells (pDC) play a crucial role in antitumor and antiviral responses. Despite their outstanding functional properties, their therapeutic potential has not yet been worked out. We propose a new immunotherapeutic strategy based on a pDC cell line irradiated and pulsed with tumor or viral antigens. GENiusVac allows the induction of multispecific and highly functional cytotoxic cell responses directed against viral or tumor targets. We demonstrated the potential of this strategy in vitro, its therapeutic efficacy in vivo in a humanized mouse model, and its clinical relevance ex vivo from melanoma patients' cells. GENiusVac highlights pDCs as potent vector of immunotherapy and provide a way to exploit them in cell therapy to fight cancer or chronic viral infections.

5 Article A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells. 2010

Aspord, Caroline / Charles, Julie / Leccia, Marie-Therese / Laurin, David / Richard, Marie-Jeanne / Chaperot, Laurence / Plumas, Joel. ·Etablissement Français du Sang Rhone-Alpes, R&D Laboratory, La Tronche, France. carolineaspord@yahoo.com ·PLoS One · Pubmed #20454561.

ABSTRACT: BACKGROUND: The development of effective cancer vaccines still remains a challenge. Despite the crucial role of plasmacytoid dendritic cells (pDCs) in anti-tumor responses, their therapeutic potential has not yet been worked out. We explored the relevance of HLA-A*0201 matched allogeneic pDCs as vectors for immunotherapy. METHODS AND FINDINGS: Stimulation of PBMC from HLA-A*0201(+) donors by HLA-A*0201 matched allogeneic pDCs pulsed with tumor-derived peptides triggered high levels of antigen-specific and functional cytotoxic T cell responses (up to 98% tetramer(+) CD8 T cells). The pDC vaccine demonstrated strong anti-tumor therapeutic in vivo efficacy as shown by the inhibition of tumor growth in a humanized mouse model. It also elicited highly functional tumor-specific T cells ex-vivo from PBMC and TIL of stage I-IV melanoma patients. Responses against MelA, GP100, tyrosinase and MAGE-3 antigens reached tetramer levels up to 62%, 24%, 85% and 4.3% respectively. pDC vaccine-primed T cells specifically killed patients' own autologous melanoma tumor cells. This semi-allogeneic pDC vaccine was more effective than conventional myeloid DC-based vaccines. Furthermore, the pDC vaccine design endows it with a strong potential for clinical application in cancer treatment. CONCLUSIONS: These findings highlight HLA-A*0201 matched allogeneic pDCs as potent inducers of tumor immunity and provide a promising immunotherapeutic strategy to fight cancer.

6 Article Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. 2010

Charles, Julie / Di Domizio, Jérémy / Salameire, Dimitri / Bendriss-Vermare, Nathalie / Aspord, Caroline / Muhammad, Ramzan / Lefebvre, Christine / Plumas, Joël / Leccia, Marie-Thérèse / Chaperot, Laurence. ·INSERM U823, Centre de Recherche Albert Bonniot, Immunobiologie et Immunothérapie des Cancers, Université Joseph Fourier, R&D Laboratory, EFS Rhônes-Alpes, 29 Avenue Maquis du Gresivaudan, La Tronche, France. ·J Invest Dermatol · Pubmed #20220766.

ABSTRACT: Dendritic cells (DCs) are central cells in the development of antitumor immune responses, but the number and function of these cells can be altered in various cancers. Whether these cells are affected during the development of melanoma is not known. We investigated the presence, phenotype, and functionality of circulating myeloid DCs (MDCs) and plasmacytoid DCs (PDCs) in newly diagnosed melanoma patients, compared to controls. The frequencies of PDCs and MDCs were equivalent in melanoma patients as compared with normal subjects. Both circulating DC subsets were immature, but on ex vivo stimulation with R848 they efficiently upregulated their expression of costimulatory molecules. We found that circulating DCs from melanoma patients and controls displayed similar pattern of expression of the chemokine receptors CXCR3, CXCR4, CCR7, and CCR10. Strikingly, PDCs from melanoma patients expressed higher levels of CCR6 than control PDCs, and were able to migrate toward CCL20. Further data showed that CCR6-expressing PDCs were present in melanoma primary lesions, and that CCL20 was produced in melanoma tumors. These results suggest that PDCs and MDCs are functional in melanoma patients at the time of diagnosis, and that CCL20 may participate to their recruitment from the blood to the tumor.